Research graph
References from Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
The 2023 impact of inflammatory bowel disease in Canada: epidemiology of IBD
10.1093/jcag/gwad020 · 2023 · External reference
Crohn’s disease
10.1016/s0140-6736(16)31711-1 · 2017 · External reference
Ulcerative colitis
10.1016/s0140-6736(16)32126-2 · 2017 · External reference
Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases
10.1097/mib.0000000000000620 · 2016 · External reference
Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment
10.1016/j.crohns.2012.01.007 · 2012 · External reference
Maintenance therapy options for ulcerative colitis
10.1080/14656566.2016.1179281 · 2016 · External reference
ACG clinical guideline: management of Crohn’s disease in adults
10.1038/ajg.2018.27 · 2018 · External reference
Bowel urgency in ulcerative colitis: current perspectives and future directions
10.14309/ajg.0000000000002450 · 2023 · External reference
What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study
10.1093/ecco-jcc/jjac136 · 2023 · External reference
Patient perception of bowel urgency and remission in moderately to severely active Crohn’s disease or ulcerative colitis: a qualitative study
10.1186/s41687-024-00802-8 · 2024 · External reference
Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies
10.1093/crocol/otae001 · 2024 · External reference
Living with inflammatory bowel disease: online surveys evaluating patient perspectives on treatment satisfaction and health-related quality of life
10.1093/crocol/otac035 · 2022 · External reference
Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy
10.1093/ibd/izy404 · 2019 · External reference
Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission
10.1093/crocol/otac044 · 2023 · External reference
Incorporating patient experience into drug development for ulcerative colitis: development of the urgency numeric rating scale, a patient-reported outcome measure to assess bowel urgency in adults
10.1186/s41687-022-00438-2 · 2022 · External reference
Psychometric evaluation of the urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis
10.1186/s41687-022-00521-8 · 2022 · External reference
Novel therapeutic targets for inflammatory bowel disease
10.1016/j.jaut.2017.07.004 · 2017 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Vedolizumab as induction and maintenance therapy for Crohn’s disease
10.1056/nejmoa1215739 · 2013 · External reference
Vedolizumab as induction and maintenance therapy for ulcerative colitis
10.1056/nejmoa1215734 · 2013 · External reference
Effectiveness of intravenous vedolizumab induction and dose escalation in ulcerative colitis and Crohn’s disease; a large-scale, Canadian real-world cohort
2024 · External reference
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
10.1007/s00535-018-1480-0 · 2018 · External reference
Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease
10.1016/j.cgh.2016.02.016 · 2016 · External reference
Bowel urgency in Crohn’s disease: effects of mirikizumab in a randomized controlled phase 3 study
10.1016/j.cgh.2025.06.015 · 26 · External reference
Predictors of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort
10.1007/s10620-021-06907-5 · 2022 · External reference
Unresolved reference
External reference
